

# Lesinurad

**Catalog No: tcsc1389**



## Available Sizes

---

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

878672-00-5

**Formula:**

$C_{17}H_{14}BrN_3O_2S$

**Pathway:**

Membrane Transporter/Ion Channel

**Target:**

URAT1

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 39$  mg/mL (96.47 mM)

**Alternative Names:**

RDEA594

**Observed Molecular Weight:**

404.28


## Product Description

Lesinurad is a **URAT1** and **OAT** inhibitor, is determined to be a substrate for the kidney transporters **OAT1** and **OAT3** with **K<sub>m</sub>** values of 0.85 and 2  $\mu\text{M}$ , respectively.

IC<sub>50</sub> & Target: Km: 0.85  $\mu\text{M}$  (OAT1), 2  $\mu\text{M}$  (OAT3)<sup>[1]</sup>

**In Vitro:** Lesinurad is a novel selective uric acid reabsorption inhibitor (SURI). Lesinurad is determined to be a substrate for the kidney transporters organic anion transporter (OAT1) and OAT3 with **K<sub>m</sub>** values of 0.85 and 2  $\mu\text{M}$ , respectively<sup>[1]</sup>. Lesinurad (RDEA594) is a URAT1 and OAT inhibitor, which increases proximal renal tubule urate excretion<sup>[2]</sup>. Lesinurad (RDEA594) is a potential uric acid lowering agent through inhibition of uric acid reuptake, and exhibits favorable p450 profiles, inhibits CYP2C9 and CYP2C8 with IC<sub>50</sub> of 14.4  $\mu\text{M}$  and 16.2  $\mu\text{M}$ , respectively. IC<sub>50</sub>s of Lesinurad are all above 100  $\mu\text{M}$  for CYP1A2, CYP2C19, and CYP2D6<sup>[3]</sup>.

**In Vivo:** Lesinurad (RDEA594) shows better pharmacokinetics than its pro-drug RDEA806. The 100 mg dose of Lesinurad exhibits a pharmacological effect in the range of that produced by 300 mg to 800 mg single doses of RDEA806<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!